Correspondence
SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

https://doi.org/10.1016/S2213-8587(17)30257-7Get rights and content

References (4)

  • B Neal et al.

    Canagliflozin and cardiovascular and renal events in type 2 diabetes

    N Engl J Med

    (2017)
  • GP Fadini et al.

    SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System

    Diabetologia

    (2017)
There are more references available in the full text version of this article.

Cited by (113)

View all citing articles on Scopus
View full text